<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10496358</article-id><article-id pub-id-type="pmc">2362873</article-id><article-id pub-id-type="pii">6690693</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6990693</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ardizzoni</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grossi</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Scolaro</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Giudici</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Foppiano</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Boni</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Tixi</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cosso</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><name><surname>Mereu</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ratto</surname><given-names>G Battista</given-names></name><xref ref-type="aff" rid="aff5">6</xref></contrib><contrib contrib-type="author"><name><surname>Vitale</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Rosso</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Medical Oncology I, <label>2</label>Division of Radiation Oncology, <label>3</label>Unit of Clinical Epidemiology and Trials, <label>4</label>Service of Radiology, Istituto Nazionale per la Ricerca sul Cancro and Centro di Biotecnologie Avanzate, Largo R Benzi 10, Genova, 16132, Italy</aff><aff id="aff5"><label>5</label>Center of Respiratory Endoscopy, <label>6</label>Chair of Thoracic Surgery, Universit&#x000e0; degli studi di Genova, Genova, Italy</aff><pub-date pub-type="ppub"><month>09</month><year>1999</year></pub-date><volume>81</volume><issue>2</issue><fpage>310</fpage><lpage>315</lpage><history><date date-type="received"><day>27</day><month>10</month><year>1998</year></date><date date-type="rev-recd"><day>25</day><month>03</month><year>1999</year></date><date date-type="accepted"><day>12</day><month>04</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Both induction chemotherapy and concurrent low-dose cisplatin have been shown to improve results of thoracic irradiation in the treatment of locally advanced non-small-cell lung cancer (NSCLC). This phase II study was designed to investigate activity and feasibility of a novel chemoradiation regimen consisting of induction chemotherapy followed by standard radiotherapy and concurrent daily low-dose cisplatin. Previously untreated patients with histologically/cytologically proven unresectable stage IIIA/B NSCLC were eligible. Induction chemotherapy consisted of vinblastine 5 mg m<sup>&#x02212;2</sup> intravenously (i.v.) on days 1, 8, 15, 22 and 29, and cisplatin 100 mg m<sup>&#x02212;2</sup> i.v. on days 1 and 22 followed by continuous radiotherapy (60 Gy in 30 fractions) given concurrently with daily cisplatin at a dose of 5 mg m<sup>&#x02212;2</sup> i.v. Thirty-two patients were enrolled. Major toxicity during induction chemotherapy was haematological: grade III&#x02013;IV leukopenia was observed in 31&#x00025; and grade II anaemia in 16&#x00025; of the patients. The most common severe toxicity during concurrent chemoradiation consisted of grade III leukopenia (21&#x00025; of the patients); grade III oesophagitis occurred in only two patients and pulmonary toxicity in one patient who died of this complication. Eighteen of 32 patients (56&#x00025;, 95&#x00025; CI 38&#x02013;73&#x00025;) had a major response (11 partial response, seven complete response). With a median follow-up of 38.4 months, the median survival was 12.5 months and the actuarial survival rates at 1, 2 and 3 years were 52&#x00025;, 26&#x00025; and 19&#x00025; respectively. The median event-free survival was 8.3 months with a probability of 40&#x00025;, 23&#x00025; and 20&#x00025; at 1, 2 and 3 years respectively. Induction chemotherapy followed by concurrent daily low-dose cisplatin and thoracic irradiation, in patients with locally advanced NSCLC, is active and feasible with minimal non-haematological toxicity. Long-term survival results are promising and appear to be similar to those of more toxic chemoradiation regimens, warranting further testing of this novel chemoradiation strategy. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>induction chemotherapy</kwd><kwd>concurrent chemoradiation in NSCLC</kwd><kwd>phase II study</kwd></kwd-group></article-meta></front></article>


